BR112019016705A2 - composições e métodos para tratar doença associada à permeabilidade do epitélio intestinal - Google Patents

composições e métodos para tratar doença associada à permeabilidade do epitélio intestinal Download PDF

Info

Publication number
BR112019016705A2
BR112019016705A2 BR112019016705A BR112019016705A BR112019016705A2 BR 112019016705 A2 BR112019016705 A2 BR 112019016705A2 BR 112019016705 A BR112019016705 A BR 112019016705A BR 112019016705 A BR112019016705 A BR 112019016705A BR 112019016705 A2 BR112019016705 A2 BR 112019016705A2
Authority
BR
Brazil
Prior art keywords
larazotide
derivative
subject
release
fact
Prior art date
Application number
BR112019016705A
Other languages
English (en)
Portuguese (pt)
Inventor
BLIKSLAGER Anthony
Madan Jay
Original Assignee
Innovate Biopharmaceuticals Inc
Univ North Carolina State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovate Biopharmaceuticals Inc, Univ North Carolina State filed Critical Innovate Biopharmaceuticals Inc
Publication of BR112019016705A2 publication Critical patent/BR112019016705A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112019016705A 2017-02-10 2018-02-12 composições e métodos para tratar doença associada à permeabilidade do epitélio intestinal BR112019016705A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762457279P 2017-02-10 2017-02-10
PCT/US2018/017813 WO2018148655A1 (en) 2017-02-10 2018-02-12 Compositions and methods for treating disease associated with permeability of intestinal epithelium

Publications (1)

Publication Number Publication Date
BR112019016705A2 true BR112019016705A2 (pt) 2020-04-07

Family

ID=63107916

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019016705A BR112019016705A2 (pt) 2017-02-10 2018-02-12 composições e métodos para tratar doença associada à permeabilidade do epitélio intestinal

Country Status (11)

Country Link
US (3) US11058902B2 (https=)
EP (2) EP3579862A4 (https=)
JP (1) JP2020507626A (https=)
KR (1) KR20190121785A (https=)
CN (1) CN110891587A (https=)
AU (1) AU2018219367A1 (https=)
BR (1) BR112019016705A2 (https=)
CA (1) CA3052975A1 (https=)
MX (1) MX2019009586A (https=)
WO (2) WO2018148655A1 (https=)
ZA (1) ZA201905439B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11058902B2 (en) * 2017-02-10 2021-07-13 9 Meters Biopharma, Inc. Compositions and methods for treating disease associated with permeability of intestinal epithelium
WO2019165346A1 (en) 2018-02-23 2019-08-29 Innovate Biopharmaceuticals, Inc. Compounds and methods for treating tight junction permeability
US20210100868A1 (en) * 2018-03-19 2021-04-08 North Carolina State University Compositions and methods for treating or preventing gastrointestinal damage associated with nsaid therapy
WO2019183036A1 (en) 2018-03-19 2019-09-26 Innovate Biopharmaceuticals, Inc. Compositions and methods for potentiating immune checkpoint inhibitor therapy
WO2021034629A1 (en) * 2019-08-16 2021-02-25 9 Meters Biopharma, Inc. Larazotide formulations
AU2021255955A1 (en) * 2020-04-15 2022-11-10 Interlude Biopharma Co. Larazotide derivatives comprising d-amino acids
WO2023154770A1 (en) * 2022-02-09 2023-08-17 9 Meters Biopharma, Inc. Compositions and methods for inhibiting rho kinase
CN114788837B (zh) * 2022-06-07 2023-09-05 青岛东海药业有限公司 一种组合物及其在制备治疗和/或预防化疗引起的恶心呕吐的药物中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665389A (en) 1995-05-24 1997-09-09 University Of Maryland At Baltimore Oral dosage composition for intestinal delivery and method of treating diabetes
US5827534A (en) 1995-05-24 1998-10-27 University Of Maryland At Baltimore Oral dosage composition comprising zonnula occludens toxin and a therapeutic agent for intestinal delivery
US5945510A (en) 1997-05-21 1999-08-31 University Of Maryland, Baltimore Substantially pure zonulin, a physiological modulator of mammalian tight junctions
US6458925B1 (en) 1998-08-03 2002-10-01 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same
AU2001249067A1 (en) 2000-05-19 2001-12-03 University Of Maryland, Baltimore Method of use of peptide antagonists of zonulin to prevent or delay the onset ofdiabetes
US20060062758A1 (en) * 2004-09-21 2006-03-23 Nastech Pharmaceutical Comapny Inc. Tight junction modulator peptide PN159 for enhanced mucosal delivery of therapeutic compounds
US20090176244A1 (en) 2005-05-13 2009-07-09 Bai Julio Methods and compositions for the diagnosis of crohn's disease
CN101189518A (zh) * 2005-05-13 2008-05-28 马里兰巴尔的摩大学 评价治疗方案有效性的方法
AR057058A1 (es) * 2005-06-09 2007-11-14 Alba Therapeutics Corp Metodo para usar antagonistas de zonulina para prevenir la perdida o para regenerar celulas pancreaticas
MX2008010221A (es) * 2006-02-09 2009-03-05 Alba Therapeutics Corp Formulaciones para un efector de union ajustada.
WO2008043107A2 (en) 2006-10-06 2008-04-10 Alba Therapeutics Corporation Use of tight junction antagonists to treat inflammatory bowel disease
US8034776B2 (en) 2006-10-26 2011-10-11 Alba Therapeutics Corporation Materials and methods for the treatment of celiac disease
US20110201543A1 (en) 2007-06-29 2011-08-18 Blake Paterson Use of tight junction antagonists in the treatment of acute lung injury and acute respiratory distress
US8198233B2 (en) 2007-07-26 2012-06-12 Alba Therapeutics Corporation Synthetic peptides that enhance tight junction permeability
WO2009052489A2 (en) 2007-10-19 2009-04-23 Alba Therapeutics Corporation Novel inhibitors of mammalian tight junction opening
EP2062909A1 (en) * 2007-11-21 2009-05-27 SOLVAY (Société Anonyme) Peptide production and purification process
US9051349B2 (en) 2007-11-21 2015-06-09 Alba Therapeutics Corporation Larazotide acetate compositions
CN101440369A (zh) * 2008-03-26 2009-05-27 华东师范大学 一种缺失的霍乱弧菌封闭带毒素的表达方法及应用
WO2009137572A2 (en) * 2008-05-06 2009-11-12 Alba Therapeutics Corporation Inhibition of gliadin peptides
WO2010042821A1 (en) * 2008-10-10 2010-04-15 Nationwide Children's Hospital Method of treating necrotizing enterocolitis using heparin binding epidermal growth factor
EP3125870A4 (en) * 2014-04-04 2017-12-13 Alba Therapeutics Corporation Methods of treating celiac disease with larazotide
CA2955425A1 (en) * 2014-07-17 2016-01-21 Jerome Schentag Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems
US11058902B2 (en) * 2017-02-10 2021-07-13 9 Meters Biopharma, Inc. Compositions and methods for treating disease associated with permeability of intestinal epithelium

Also Published As

Publication number Publication date
US20210299481A1 (en) 2021-09-30
EP3579862A1 (en) 2019-12-18
CN110891587A (zh) 2020-03-17
WO2018148655A1 (en) 2018-08-16
CA3052975A1 (en) 2018-08-16
ZA201905439B (en) 2021-02-24
EP3579863A4 (en) 2020-11-11
MX2019009586A (es) 2019-11-11
US20190358288A1 (en) 2019-11-28
EP3579863A1 (en) 2019-12-18
US20190358289A1 (en) 2019-11-28
US11058902B2 (en) 2021-07-13
JP2020507626A (ja) 2020-03-12
WO2018148654A1 (en) 2018-08-16
AU2018219367A1 (en) 2019-09-19
KR20190121785A (ko) 2019-10-28
EP3579862A4 (en) 2020-12-23

Similar Documents

Publication Publication Date Title
BR112019016705A2 (pt) composições e métodos para tratar doença associada à permeabilidade do epitélio intestinal
ES2924041T3 (es) Materia fecal para la prevención o el tratamiento de enfermedades autoinmunes
JP2008143914A (ja) 炎症性腸疾患を治療するための医薬組成物
US20190262407A1 (en) Probiotic compositions and methods of use thereof
CA3023042A1 (en) Compositions and methods for the treatment or prevention of oxalate-related disorders
TW202547550A (zh) 司馬魯肽在醫學上的用途
JP2025186415A (ja) 非経口栄養製剤
CN111328279A (zh) 口服利福霉素sv组合物
JP7700109B2 (ja) 胃腸の健康組成物
US20210100868A1 (en) Compositions and methods for treating or preventing gastrointestinal damage associated with nsaid therapy
Sarangi et al. Tolerability and efficacy of racecadotril in acute diarrhoea, a prospective, randomised, parallel study in an indian tertiary care teaching hospital
CN105209043B (zh) 噻唑并嘧啶酮用于治疗炎症性肠病的应用
JP2023550772A (ja) 酪酸アルギニンを含む非経口栄養製剤
RU2793319C2 (ru) Композиции рифамицина sv для перорального применения
RU2812928C2 (ru) Твердая композиция для доставки
Özgüney Conventional and novel pharmaceutical dosage forms on prevention of gastric ulcers
CA2974055A1 (en) A combination of hydromorphone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk forintestinal bacterial translocation
WO2013186191A1 (en) Formulations of metronidazole for the treatment of pouchitis

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements